Moderna (MRNA) Projected to Post Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) is expected to release its Q4 2025 results before the market opens on Friday, February 13th. Analysts expect Moderna to post earnings of ($2.79) per share and revenue of $611.14 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 13, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business’s revenue for the quarter was down 45.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 earnings per share. On average, analysts expect Moderna to post $-10 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Moderna Trading Down 4.4%

Shares of NASDAQ MRNA opened at $40.87 on Friday. Moderna has a 12-month low of $22.28 and a 12-month high of $55.20. The company has a market cap of $15.97 billion, a PE ratio of -5.06 and a beta of 1.32. The stock has a 50 day simple moving average of $35.35 and a 200-day simple moving average of $29.54.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MRNA. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research note on Monday, January 5th. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Monday, October 20th. TD Cowen reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Finally, Wolfe Research reiterated an “underperform” rating and set a $17.00 price objective on shares of Moderna in a research note on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of “Reduce” and a consensus target price of $28.77.

Insider Activity

In related news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the sale, the director directly owned 3,924 shares in the company, valued at $115,679.52. The trade was a 85.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of institutional investors and hedge funds have recently modified their holdings of MRNA. Invesco Ltd. boosted its stake in shares of Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after acquiring an additional 1,115,131 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in shares of Moderna during the second quarter valued at $23,192,000. Bank of America Corp DE boosted its position in shares of Moderna by 84.3% in the 2nd quarter. Bank of America Corp DE now owns 1,779,309 shares of the company’s stock valued at $49,091,000 after purchasing an additional 813,974 shares during the period. Theleme Partners LLP increased its stake in Moderna by 8.6% in the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after purchasing an additional 626,420 shares in the last quarter. Finally, Jump Financial LLC raised its holdings in Moderna by 1,920.3% during the 3rd quarter. Jump Financial LLC now owns 498,460 shares of the company’s stock worth $12,875,000 after buying an additional 473,788 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.